Ligand Pharmaceuticals Incorpor (LGND) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.67
- Estimate
- $2.33
- Surprise
- +14.7%
- Revenue (period 2026-09-30)
- $78.7M
- Score at report (before → after)
- 6.4 → 5.0/10
Revenue source: xbrl.
How the report landed
Ligand Pharmaceuticals Incorpor (LGND) beat the $2.33 estimate with adjusted EPS of $2.67 — a large 14.7% upside surprise. TrendMatrix's engine moved from Hold (6.4/10) to Sell at 5.0/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LGND Hold at 4.2/10.
3 of the last 4 quarters beat the estimate; this quarter's +14.7% surprise compares with a +15.4% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- Strong earnings beat streak (3/4)
- Positive news sentiment (+0.67)
What argues against it
- Concentration risk — Supplier: Hovione
- Thin upside margin: 5.3%
- Leverage penalty (D/E 1.2): -0.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $298.46
- Price target
- $314.31
- Stop
- $282.86
- Upside to target
- +5.3%
- Reward-to-risk
- 0.7:1
The stock trades at 120.9× trailing but 24.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
LGND at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.88B
- P/E (fwd)
- 24.6
- P/E (ttm)
- 120.9
- 52-week range
- $175.89–$326.63
- Off 52-week high
- 8.6%
- RSI (14)
- 40
- Volume vs avg
- 0.57×
- Score today
- 4.2/10